This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Agency
Enter a search term or FR citation e.g.88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN
Choosing an item fromfull text search results will bring you to those results. Pressing enter in the search box will also bring you to search results. Choosing an item fromsuggestions will bring you directly to the content.
Background and more details are available in theSearch & Navigation guide.
Enter a search term or FR citation e.g.88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN
Choosing an item fromfull text search results will bring you to those results. Pressing enter in the search box will also bring you to search results. Choosing an item fromsuggestions will bring you directly to the content.
Background and more details are available in theSearch & Navigation guide.
Food and Drug Administration
Food and Drug AdministrationThe Food and Drug Administration (FDA) is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, the Nation's food supply, cosmetics, and products that emit radiation. FDA is also responsible for advancing the public health by accelerating innovations to make medicines more effective and providing the public with accurate, science-based information on medicines and food to improve their health. FDA plays a significant role in addressing the Nation's counterterrorism capability and ensuring the security of the food supply.
- Agency URL:
- http://www.fda.gov/
- Parent Agency
- Health and Human Services Department
ListingofSignificant Documents
Showing 1-5 of500+ results since 1994. Viewmore results.
Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products; Withdrawal
by theFood and Drug Administration on11/28/2025.
The Food and Drug Administration (FDA, Agency, or we) is announcing the withdrawal of the proposed rule entitled "Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products," which published in the Federal Register of December 27, 2024. FDA is taking this action in response to comments received during the comment...
Nonprescription Drug Product With an Additional Condition for Nonprescription Use
by theFood and Drug Administration on03/25/2025.
In accordance with the memorandum of January 20, 2025, from the President, entitled "Regulatory Freeze Pending Review," the effective date of the final rule, entitled "Nonprescription Drug Product With an Additional Condition for Nonprescription Use," (ACNU) was delayed until March 21, 2025. Additional time is needed for review; therefore, the...
Nonprescription Drug Product With an Additional Condition for Nonprescription Use
by theFood and Drug Administration on01/27/2025.
In accordance with the memorandum of January 20, 2025, from the President, entitled "Regulatory Freeze Pending Review," the effective date of the final rule, entitled "Nonprescription Drug Product With an Additional Condition for Nonprescription Use," (ACNU) is delayed until March 21, 2025.
Food Labeling: Front-of-Package Nutrition Information
by theFood and Drug Administration on01/16/2025.
The Food and Drug Administration (FDA or we) proposes to require front-of-package nutrition labels on most foods that must bear a Nutrition Facts label. This action, if finalized, would require the display of a compact informational box containing certain nutrient information on the principal display panel. The box would provide consumers,...
Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products
by theFood and Drug Administration on12/27/2024.
The Food and Drug Administration (FDA, the Agency, or we) is proposing to require testing of talc-containing cosmetic products using standardized testing methods for detecting and identifying asbestos that may be present as a contaminant in talc. We are also proposing corresponding adulteration provisions. Asbestos is a potential contaminant in...
ListingofRecently Published Documents
Showing 1-10 of23,000+ results since 1994. Viewmore results.
Determination of Regulatory Review Period for Purposes of Patent Extension; KEBILIDI
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEBILIDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for...
Determination of Regulatory Review Period for Purposes of Patent Extension; AMTAGVI
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AMTAGVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for...
Determination of Regulatory Review Period for Purposes of Patent Extension; CRENESSITY
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRENESSITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce,...
Determination of Regulatory Review Period for Purposes of Patent Extension; AUCATZYL
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AUCATZYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for...
Determination of Regulatory Review Period for Purposes of Patent Extension; ATTRUBY
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ATTRUBY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for...
Determination of Regulatory Review Period for Purposes of Patent Extension; ALYFTREK
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALYFTREK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce,...
Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals; Guidance for Industry; Availability
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry (GFI) #273 entitled "Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals." This guidance document provides recommendations on how sponsors may voluntarily establish defined...
Determination of Regulatory Review Period for Purposes of Patent Extension; RYTELO
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYTELO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for...
Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA
by theFood and Drug Administration on02/13/2026.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLUJEPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce,...
Certification Process for Designated Medical Gases; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request
by theFood and Drug Administration on02/12/2026.
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Certification Process for Designated Medical Gases." This guidance explains how FDA administers the certification process and describes the annual reporting requirements for designated medical gases (DMGs)....